Studies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLC – OncLive
OncLive |
Studies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLC
OncLive With durvalumab (Imfinzi) being hailed as a potentially practice-changing therapy in locally advanced non–small cell lung cancer (NSCLC), ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease. "We have a … |
